Danvatirsen
- Generic Name
- Danvatirsen
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1402357-06-5
- Unique Ingredient Identifier
- 31N550RD05
- Background
Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).
- Associated Conditions
- -
- Associated Therapies
- -
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT05986240
- Locations
- ๐บ๐ธ
M.D. Anderson Cancer Center, Department of Leukemia, Houston, Texas, United States
๐บ๐ธMontefiore Medical Center, Bronx, New York, United States
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Flamingo Therapeutics NV
- Target Recruit Count
- 81
- Registration Number
- NCT05814666
- Locations
- ๐บ๐ธ
University of Illinois Cancer Center, Chicago, Illinois, United States
๐บ๐ธMary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
๐บ๐ธMorristown Medical Center, Morristown, New Jersey, United States
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT03819465
- Locations
- ๐น๐ญ
Research Site, Hat Yai, Thailand
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
- Conditions
- Stage IIIB Lung Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Advanced Colorectal CarcinomaAdvanced Lung Non-Small Cell CarcinomaRefractory Pancreatic CarcinomaStage IIIB Colorectal Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVA Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT02983578
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.